The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | FORTE: effective treatment of newly diagnosed MM with KRd
The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for newly diagnosed multiple myeloma (MM). Francesca Gay, MD, from the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy, discusses the results presented from this study at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. While both therapies were effective and well tolerated, KRd treatment yielded better overall responses, in addition to improved rates of MRD negativity, in both high- and low-risk patients.
